{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T08:39:44Z","timestamp":1771403984123,"version":"3.50.1"},"reference-count":35,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Evidence for neoadjuvant androgen deprivation therapy (ADT) before radical prostatectomy (RP) remains inconclusive, and current guidelines do not endorse its routine use. Objective: We aimed to evaluate the impact of neoadjuvant ADT on surgical and oncologic outcomes in a Singaporean cohort undergoing radical prostatectomy. Design, setting, and participants: In this retrospective study, 1091 men underwent RP between 2013 and 2024; a total of 105 received neoadjuvant ADT and 986 did not. A 1:1 propensity score-matched analysis was performed on age, PSA, PSA density, Gleason score, clinical T-stage, and receipt of adjuvant therapies, yielding 105 matched pairs. Outcome measurements and statistical analysis: The primary outcome was biochemical recurrence (BCR). Secondary surgical outcomes included operative time, estimated blood loss, length of stay, catheter duration, and postoperative complications. Secondary oncologic outcomes included extracapsular extension, margin status, seminal vesicle invasion, lymph node involvement, clinical-to-pathological T-stage downstaging, Gleason score decrease, and PSA decrease. Kaplan\u2013Meier survival and univariable linear and logistic regression analyses were used. Subgroup analysis was performed using stratified odds ratios to identify clinical subgroups that derived the greatest benefit from neoadjuvant ADT in terms of biochemical recurrence reduction. Results and limitations: After matching, neoadjuvant ADT was associated with a lower rate of extracapsular extension (30.8% vs. 51.4%, p = 0.004), positive surgical margins (18.4% vs. 39.4%, p = 0.002), lymph node involvement (1.0% vs. 13.0%, p = 0.002), and biochemical recurrence (4.8% vs. 18.1%, p = 0.005). There were no significant differences in operative time, blood loss, length of stay, or complication rates. Before matching, 2-year biochemical recurrence-free survival (BCR-FS) did not differ significantly (93.0% vs. 88.2%, log-rank p = 0.26), but after matching, BCR-FS favored ADT (93.0% vs. 81.8%, log-rank p = 0.02). Subgroup analysis showed that the reduction in biochemical recurrence with neoadjuvant ADT was more pronounced in patients with PSA density \u2265 0.20 ng\/mL2, Gleason score \u2265 8, and clinical T3 disease. Limitations include the retrospective design and potential residual confounding. Conclusions: Neoadjuvant ADT prior to RP significantly reduces locoregional spread and biochemical recurrence without increasing perioperative morbidity. Prospective trials are needed to confirm its benefit in high-risk prostate cancer.<\/jats:p>","DOI":"10.3390\/cancers18040661","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:50:30Z","timestamp":1771401030000},"page":"661","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant ADT for Asian Patients Undergoing Robotic Radical Prostatectomy Is the Conversation Over?\u2014A Propensity-Matched Comparison"],"prefix":"10.3390","volume":"18","author":[{"given":"John Joson","family":"Ng","sequence":"first","affiliation":[{"name":"Duke-NUS Medical School, Singapore 169857, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Urology, Singapore General Hospital, Singapore 169608, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Urology, Singapore General Hospital, Singapore 169608, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Guang","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Urology, Singapore General Hospital, Singapore 169608, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kae Jack","family":"Tay","sequence":"additional","affiliation":[{"name":"Department of Urology, Singapore General Hospital, Singapore 169608, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Urology, Singapore General Hospital, Singapore 169608, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Yuen","sequence":"additional","affiliation":[{"name":"Department of Urology, Singapore General Hospital, Singapore 169608, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3844-7567","authenticated-orcid":false,"given":"Kenneth","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Singapore General Hospital, Singapore 169608, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/pcan.2013.46","article-title":"Very-high-risk localized prostate cancer: Definition and outcomes","volume":"17","author":"Sundi","year":"2013","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_3","unstructured":"Health Promotion Board (2025, June 09). Singapore Cancer Registry Annual Report 2022, Available online: https:\/\/www.nrdo.gov.sg\/docs\/librariesprovider3\/default-document-library\/scr-ar-2022_web-report6c6e8522-cf39-416f-9390-5fe903065927.pdf?sfvrsn=3712e8bb_1."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e034331","DOI":"10.1136\/bmjopen-2019-034331","article-title":"Local and systemic morbidities of de novo metastatic prostate cancer in Singapore: Insight from 685 consecutive patients from a large prospective Uro-oncology registry","volume":"10","author":"Tan","year":"2020","journal-title":"BMJ Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of Prostate Cancer\u2013Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1002\/cncr.10977","article-title":"Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above","volume":"95","author":"Kupelian","year":"2002","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zhang, L., Zhao, H., Wu, B., Zha, Z., Yuan, J., and Feng, Y. (2021). The Impact of Neoadjuvant Hormone Therapy on Surgical and Oncological Outcomes for Patients with Prostate Cancer Before Radical Prostatectomy: A Systematic Review and Meta-Analysis. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.615801"},{"key":"ref_8","first-page":"CD006019","article-title":"Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer","volume":"2010","author":"Kumar","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5489\/cuaj.7041","article-title":"Do androgen-directed therapies improve outcomes in prostate cancer patients undergoing radical prostatectomy? A systematic review and meta-analysis","volume":"15","author":"Nayak","year":"2021","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2008.08.002","article-title":"A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma","volume":"35","author":"Shelley","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-016-0859-0","article-title":"The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: A multi-institutional analysis","volume":"34","author":"Narita","year":"2016","journal-title":"Med. Oncol."},{"key":"ref_12","first-page":"170","article-title":"Mortality Rate Estimation Models for Patients with Prostate Cancer Diagnosis","volume":"10","author":"Kraujalis","year":"2022","journal-title":"Balt. J. Mod. Comput."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s11845-021-02730-z","article-title":"The role of data science in healthcare advancements: Applications, benefits, and future prospects","volume":"191","author":"Subrahmanya","year":"2021","journal-title":"Ir. J. Med. Sci."},{"key":"ref_14","unstructured":"EAU Guidelines (2025). Edn. Presented at the EAU Annual Congress Madrid 2025, EAU Guidelines Office."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management","volume":"208","author":"Eastham","year":"2022","journal-title":"J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yanagisawa, T., Rajwa, P., Quhal, F., Kawada, T., Bekku, K., Laukhtina, E., von Deimling, M., Chlosta, M., Karakiewicz, P.I., and Kimura, T. (2023). Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review. J. Pers. Med., 13.","DOI":"10.3390\/jpm13040641"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.euf.2020.05.020","article-title":"A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic","volume":"6","author":"Heldwein","year":"2020","journal-title":"Eur. Urol. Focus"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eururo.2020.04.056","article-title":"European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era","volume":"78","author":"Ribal","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"102346","DOI":"10.1016\/j.clgc.2025.102346","article-title":"Efficacy of Neoadjuvant Hormonal Therapy for High-Risk Prostate Cancer Undergoing Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Study Using Propensity Score-Matched Analysis in Japan","volume":"23","author":"Nezasa","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0022-5347(05)65393-1","article-title":"The Lupron Depot Neoadjuvant Prostate Cancer Study Group. Neoadjuvant Androgen Ablation Before Radical Prostatectomy in cT2bNxMo Prostate Cancer: 5-Year Results","volume":"167","author":"Soloway","year":"2002","journal-title":"J. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4111\/kju.2011.52.1.19","article-title":"Neoadjuvant Hormonal Therapy Preceding Radical Prostatectomy for Clinically Localized Prostate Cancer: Early Postoperative Complications and Biochemical Recurrence","volume":"52","author":"Yang","year":"2011","journal-title":"Korean J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.prro.2012.10.004","article-title":"Anatomic variation and dosimetric consequences of neoadjuvant hormone therapy before radiation therapy for prostate cancer","volume":"3","author":"Melancon","year":"2013","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00432-007-0204-2","article-title":"Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy","volume":"133","author":"Pu","year":"2007","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/S0022-5347(06)00260-6","article-title":"The Impact of Neoadjuvant Hormonal Therapy on the Outcome of Laparoscopic Radical Prostatectomy: A Matched Pair Analysis","volume":"175","author":"Teber","year":"2006","journal-title":"J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0022-5347(05)68092-5","article-title":"Neoadjuvant Hormonal Therapy Before Radical Prostatectomy and Risk of Prostate Specific Antigen Failure","volume":"162","author":"Meyer","year":"1999","journal-title":"J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/20514158211022216","article-title":"A cohort analysis of patients receiving neoadjuvant androgen deprivation therapy prior to robot-assisted laparoscopic prostatectomy during the COVID-19 pandemic","volume":"16","author":"Bennett","year":"2021","journal-title":"J. Clin. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Cui, F., Qiu, Y., Xu, W., Zou, C., and Fan, Y. (2024). Pretreatment prostate-specific antigen density as a predictor of biochemical recurrence in patients with prostate cancer: A meta-analysis. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12029-8"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Bejrananda, T., and Pliensiri, P. (2023). Prediction of biochemical recurrence after laparoscopic radical prostatectomy. BMC Urol., 23.","DOI":"10.1186\/s12894-023-01350-2"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/us9.0000000000000037","article-title":"Biochemical recurrence after open radical prostatectomy in a single-center cohort with a minimum follow-up of 10 years","volume":"36","author":"Stankovic","year":"2025","journal-title":"Urol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.21873\/anticanres.17129","article-title":"Predictive Factors for Early Biochemical Recurrence Following Robot-assisted Radical Prostatectomy","volume":"44","author":"Mitsunari","year":"2024","journal-title":"Anticancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/pros.23777","article-title":"Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers","volume":"79","author":"Wang","year":"2019","journal-title":"Prostate"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/S0022-5347(05)64285-1","article-title":"Neoadjuvant Therapy Before Radical Prostatectomy For Clinical T3\/T4 Carcinoma of the Prostate: 5-Year Followup, Phase II Southwest Oncology Group Study 9109","volume":"168","author":"Powell","year":"2002","journal-title":"J. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"20015","DOI":"10.1038\/s41598-020-76786-9","article-title":"The use of prostate specific antigen density to predict clinically significant prostate cancer","volume":"10","author":"Yusim","year":"2020","journal-title":"Sci. Rep."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/661\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:58:26Z","timestamp":1771401506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18040661"],"URL":"https:\/\/doi.org\/10.3390\/cancers18040661","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]}}}